HistoWiz, a biotech startup that automates histology by building an intelligent tissue platform for cancer researchers, presented its winning business idea and was named the global winner of the Create@Alibaba Cloud Startup Contest (CACSC). This was a highly competitive event with the finalists from 25 regional contests across China and international markets including Europe, Asia, the Middle East and the United States. The solutions offered by the finalists ranged from big data, artificial intelligence, new retail to smart devices.
Following an intensive pitch process, HistoWiz impressed judges with their business concepts and great commercial potential. From inception in 2013, the company now has over 1,000 paying customers from top academic institutions and pharmaceutical companies around the world, and has accumulated the world’s largest online pathology database with access to a growing network of top pathologists.
“We are thrilled to win the 2017 Create@Alibaba Cloud Startup Contest global championship. Winning this competition will help us enter the Chinese market and partner with local hospitals to provide automated histology service and pathology expertise to Chinese patients. Our intelligent tissue platform will be hosted on Alibaba Cloud. Alibaba Cloud’s scalable infrastructure will help us process and store hundreds of terabytes of pathology image data which can be used to develop automated cancer diagnostic tools,” said Ke Cheng, Founder and CEO of HistoWiz.
Original news: https://www.alibabacloud.com/press-room/histowiz-wins-the-2017-create-alibaba-cloud-global-startup-contest
HistoWiz present “Development of a cloud-based histology database and assay development for collaborative cancer research” at LeicaBio symposium. HistoWiz is uniquely positioned to bring cutting-edge web technologies and practices to histopathology, enabling researchers to maximize the impact of their work. HistoWiz proposes to build a cancer WSI database on the Cloud, and in parallel to develop a histopathological image tagging web application. These tools will allow for a novel approach to synergistically share, search, and compare histopathology research data.
By using machine learning (ML) algorithms and allowing histology service users to contribute, annotate and compare cancer tissue data across different laboratories and hospitals around the world, PathologyMap will be vital for improving cancer diagnosis, discovering insights to advance cancer research, saving money by reducing repetitive research, and accelerating drug development.
In case collaborating with NanoString, HistoWiz leverages PathologyMapTM to develop the assay of automation of nCounter® technology to detect up to 800 RNA or protein targets on one slide at high sensitivity. DNA oligonucleotides covalently bind to primary antibodies which are specific to proteins of interest. The oligonucleotides are recognized by fluorescent barcodes which are attached to the reporter probe. The reporter probes are imaged and counted to provide a readout of protein expression. HistoWiz uses digital color-coded barcode technology that is based on direct multiplexed measurement of gene expression and offers high levels of precision and sensitivity (< 1 copy per cell). The technology uses a molecular “barcodes” and single molecule imaging to detect and count hundreds of unique transcripts in a single reaction.
PathologyMap is the world’s largest, most comprehensive Cloud-based WSI database for cancer histopathology. Histowiz is capable of leveraging PathologyMap to streamline the IHC optimization process with the standardized protocol and wide range of tissues to validate an assay.